BioXcel Therapeutics, Inc. Common Stock (BTAI) is a publicly traded Healthcare sector company. As of May 21, 2026, BTAI trades at $1.09 with a market cap of $30.59M and a P/E ratio of -0.24. BTAI moved +1.39% today. Year to date, BTAI is -39.11%; over the trailing twelve months it is -23.24%. Its 52-week range spans $1.01 to $13.28. Analyst consensus is buy with an average price target of $7.67. Rallies surfaces BTAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA Accepts IGALMI At-Home sNDA with Nov. 14 PDUFA Date as BioXcel Weighs Strategic Options: FDA accepted sNDA for IGALMI at-home treatment of acute agitation in bipolar disorder and schizophrenia, setting a PDUFA date of November 14, 2026. BioXcel reported Q1 revenue of $206,000, a net loss of $12.7 million and $17.2 million in cash while engaging advisors to explore strategic options for IGALMI.
| Metric | Value |
|---|---|
| Price | $1.09 |
| Market Cap | $30.59M |
| P/E Ratio | -0.24 |
| EPS | $-4.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.28 |
| 52-Week Low | $1.01 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $680.00K |
| Net Income | $-75.33M |
| Gross Margin | 36.32% |
3 analysts cover BTAI: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.67.